JP6553069B2 - 抗ｗｔ１／ｈｌａ二重特異性抗体 - Google Patents

抗ｗｔ１／ｈｌａ二重特異性抗体 Download PDF

Info

Publication number
JP6553069B2
JP6553069B2 JP2016553248A JP2016553248A JP6553069B2 JP 6553069 B2 JP6553069 B2 JP 6553069B2 JP 2016553248 A JP2016553248 A JP 2016553248A JP 2016553248 A JP2016553248 A JP 2016553248A JP 6553069 B2 JP6553069 B2 JP 6553069B2
Authority
JP
Japan
Prior art keywords
cells
cell
tumor
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016553248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500057A (ja
JP2017500057A5 (enExample
Inventor
デイビッド シャインバーグ，
デイビッド シャインバーグ，
ジンイー シャン，
ジンイー シャン，
タオ ダオ，
タオ ダオ，
スー ヤン，
スー ヤン，
チェン リウ，
チェン リウ，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
ユーリカ セラピューティックス， インコーポレイテッド
ユーリカ セラピューティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター, ユーリカ セラピューティックス， インコーポレイテッド, ユーリカ セラピューティックス， インコーポレイテッド filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2017500057A publication Critical patent/JP2017500057A/ja
Publication of JP2017500057A5 publication Critical patent/JP2017500057A5/ja
Application granted granted Critical
Publication of JP6553069B2 publication Critical patent/JP6553069B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016553248A 2013-11-07 2014-11-07 抗ｗｔ１／ｈｌａ二重特異性抗体 Expired - Fee Related JP6553069B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361901310P 2013-11-07 2013-11-07
US61/901,310 2013-11-07
US201462037875P 2014-08-15 2014-08-15
US62/037,875 2014-08-15
PCT/US2014/064621 WO2015070061A1 (en) 2013-11-07 2014-11-07 Anti-wt1/hla bi-specific antibody

Publications (3)

Publication Number Publication Date
JP2017500057A JP2017500057A (ja) 2017-01-05
JP2017500057A5 JP2017500057A5 (enExample) 2018-05-10
JP6553069B2 true JP6553069B2 (ja) 2019-07-31

Family

ID=51987482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553248A Expired - Fee Related JP6553069B2 (ja) 2013-11-07 2014-11-07 抗ｗｔ１／ｈｌａ二重特異性抗体

Country Status (5)

Country Link
EP (1) EP3066130B1 (enExample)
JP (1) JP6553069B2 (enExample)
CN (1) CN106414500B (enExample)
ES (1) ES2742224T3 (enExample)
WO (1) WO2015070061A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
JP6862435B2 (ja) * 2015-10-09 2021-04-21 イマティクス バイオテクノロジーズ ゲーエムベーハー 抗ｗｔ１／ｈｌａ特異的抗体
CN116059316A (zh) 2015-10-23 2023-05-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
CA3068634A1 (en) 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
JP7072792B2 (ja) * 2017-12-11 2022-05-23 国立大学法人神戸大学 二重特異性抗体
BR112020011469A2 (pt) 2017-12-21 2020-11-24 F. Hoffmann-La Roche Ag anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007697VA (en) 2018-02-15 2020-09-29 Memorial Sloan Kettering Cancer Center Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
JP2021526365A (ja) * 2018-05-18 2021-10-07 チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 改善された標的化ｔ細胞療法
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EP4126044A4 (en) * 2020-04-02 2024-09-04 The Board Of Regents Of The University Of Texas System CD5L-BINDING ANTIBODIES AND USES THEREOF
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
IL300543A (en) * 2020-09-24 2023-04-01 Hoffmann La Roche Prevention or reduction of adverse effects associated with a bispecific T-cell antibody
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CA3246381A1 (en) * 2022-03-22 2023-09-28 Morphosys Ag CD3-SPECIFIC DEIMMUNEIZED ANTIBODIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
ZA200601699B (en) * 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
JP2009521474A (ja) * 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
AU2012236068A1 (en) * 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2

Also Published As

Publication number Publication date
CN106414500B (zh) 2020-04-10
JP2017500057A (ja) 2017-01-05
WO2015070061A1 (en) 2015-05-14
ES2742224T3 (es) 2020-02-13
CN106414500A (zh) 2017-02-15
EP3066130A1 (en) 2016-09-14
EP3066130B1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
EP3066130B1 (en) Anti-wt1/hla bi-specific antibody
JP7857980B2 (ja) Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用
US20220185890A1 (en) Lag-3 binding members
US10239952B2 (en) Anti-WT1/HLA bi-specific antibody
TWI786034B (zh) 靶向afp肽/mhc複合體之構築體及其用途
KR20210013160A (ko) 다중-특이적 결합 단백질 및 그에 대한 개선
BR112021010457A2 (pt) Anticorpos biespecíficos anti-muc16 x anti cd28 e usos dos mesmos
KR102602329B1 (ko) Cd3에 특이적인 항체 및 이의 용도
CN113272325A (zh) 双作用CD1d免疫球蛋白
TW201713701A (zh) 靶向ｎｙ－ｅｓｏ－１肽／ｍｈｃ複合體之構築體及其用途
KR20180011165A (ko) 신생물 치료를 위한 치료적 조합물 및 방법
US10934331B2 (en) Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
JP2018516879A (ja) Ｈｐｖ１６−ｅ７ペプチド／ｍｈｃ複合体を標的化する構築物およびその使用
CN113795262A (zh) 人源化抗dll3嵌合抗原受体及其用途
KR20210144792A (ko) 인간화된 항-클라우딘 18.2 키메라 항원 수용체 및 그의 용도
US12325754B2 (en) Cancer and B-cell related disease therapy
EP3091031A1 (en) Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
US20230057939A1 (en) Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
JP2022546364A (ja) キメラ抗原受容体系及びその使用
EP4545562A1 (en) Fusion protein comprising anti-cd73 antibody and il-2, and use thereof
US20250195645A1 (en) Combination of multispecific molecule and immune checkpoint inhibitor
US20240382592A1 (en) Methods for the treatment of anaplastic large cell lymphoma
HK1227903A1 (en) Anti-wt1/hla bi-specific antibody
HK1227903B (en) Anti-wt1/hla bi-specific antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190703

R150 Certificate of patent or registration of utility model

Ref document number: 6553069

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees